Determination of basic fibroblast growth factor levels in serum of tumor-bearing BALB/c mice treated with photodynamic therapy.
In the present study we have checked whether photodynamic therapy (PDT) may influence concentration of basic Fibroblast Growth Factor (bFGF) in in vivo conditions. We have implanted malignant tumor, i.e. BFS1 fibrosarcoma into BALB/c mice and have them treated using well established photosensitizer, hematoporphyrin derivative and new compound, hydroxygallium (III) phthalocyanine tetrasulfonic acid tetrasodium salt, BON-6. The administration of those compounds was followed by light irradiation using a halogen lamp at proper wavelengths. Our results indicate that in vivo photodynamic therapy may cause a significant decrease in bFGF concentration and this phenomenon is accompanied by prolongation of survival of treated animals.
Osiecka
Beata J
BJ
Department of Pathology, Medical University, Wrocław.
Piotr
Ziółkowski
Z
Gamian
Elzbieta
E
Lis-Nawara
Anna
A
Marszalik
Piotr
P
White
Stephen G
SG
Bonnett
Raymond
R
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017690:Cell Transplantation; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D005354:Fibrosarcoma / Q000097:blood* / Q000628:therapy*; D017324:Hematoporphyrin Derivative / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D009942:Organometallic Compounds / Q000627:therapeutic use; D017319:Photosensitizing Agents / Q000627:therapeutic use; D010789:Phototherapy
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D017319:Photosensitizing Agents; C475999:hydroxygallium (III) phthalocyanine tetrasulfonic acid tetrasodium salt; D016222:Fibroblast Growth Factor 2; D017324:Hematoporphyrin Derivative